Abraham Fong

1.8k total citations
25 papers, 1.3k citations indexed

About

Abraham Fong is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Abraham Fong has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Abraham Fong's work include Muscle Physiology and Disorders (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and HER2/EGFR in Cancer Research (4 papers). Abraham Fong is often cited by papers focused on Muscle Physiology and Disorders (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and HER2/EGFR in Cancer Research (4 papers). Abraham Fong collaborates with scholars based in United States, Canada and Germany. Abraham Fong's co-authors include Stephen J. Tapscott, Zizhen Yao, Kyle L. MacQuarrie, Robert Gentleman, Walter L. Ruzzo, Randall H. Morse, Silvère M. van der Maarel, Jennifer N. Cech, Lauren Snider and Linda N. Geng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Bioinformatics.

In The Last Decade

Abraham Fong

24 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abraham Fong United States 15 788 349 342 173 156 25 1.3k
Margaret E. Macy United States 19 521 0.7× 385 1.1× 192 0.6× 219 1.3× 329 2.1× 57 1.3k
Najim Ameziane Netherlands 19 1.3k 1.6× 504 1.4× 216 0.6× 100 0.6× 50 0.3× 47 1.7k
Roberta Sestini Italy 22 595 0.8× 362 1.0× 225 0.7× 64 0.4× 404 2.6× 45 1.3k
Adam D. Durbin United States 18 1.1k 1.4× 228 0.7× 73 0.2× 55 0.3× 348 2.2× 38 1.6k
MA Shipp United States 13 388 0.5× 544 1.6× 361 1.1× 150 0.9× 95 0.6× 14 1.2k
Inga Nagel Germany 20 359 0.5× 335 1.0× 546 1.6× 322 1.9× 166 1.1× 51 1.1k
Suvi Savola Netherlands 23 720 0.9× 317 0.9× 172 0.5× 63 0.4× 36 0.2× 44 1.4k
Alison Z. Young United States 7 931 1.2× 295 0.8× 80 0.2× 88 0.5× 64 0.4× 7 1.3k
Carrie Fitzpatrick United States 17 465 0.6× 330 0.9× 184 0.5× 97 0.6× 52 0.3× 33 1.3k
Shalini C. Reshmi United States 20 1.1k 1.3× 268 0.8× 89 0.3× 159 0.9× 242 1.6× 54 1.8k

Countries citing papers authored by Abraham Fong

Since Specialization
Citations

This map shows the geographic impact of Abraham Fong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abraham Fong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abraham Fong more than expected).

Fields of papers citing papers by Abraham Fong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abraham Fong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abraham Fong. The network helps show where Abraham Fong may publish in the future.

Co-authorship network of co-authors of Abraham Fong

This figure shows the co-authorship network connecting the top 25 collaborators of Abraham Fong. A scholar is included among the top collaborators of Abraham Fong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abraham Fong. Abraham Fong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Drakaki, Alexandra, Justin Call, Sreenivasa R Chandana, et al.. (2025). Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 3018–3018. 1 indexed citations
2.
3.
Garcia‐Manero, Guillermo, Harry P. Erba, Jessica K. Altman, et al.. (2021). Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02). Blood. 138(Supplement 1). 2601–2601. 11 indexed citations
4.
Hamilton, Erika, Gini F. Fleming, Premal H. Thaker, et al.. (2020). Abstract CT124: First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers. Cancer Research. 80(16_Supplement). CT124–CT124. 3 indexed citations
5.
Hamilton, Erika, David M. O’Malley, Roisin E. O’Cearbhaill, et al.. (2020). Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecologic Oncology. 158(3). 640–645. 16 indexed citations
6.
Morgensztern, Daniel, Melissa L. Johnson, Charles M. Rudin, et al.. (2020). SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. Lung Cancer. 145. 126–131. 19 indexed citations
7.
8.
Friedberg, Jonathan W., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2017). Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 130(26). 2829–2837. 63 indexed citations
9.
Yasenchak, Christopher A., Andres Forero‐Torres, Rodolfo Bordoni, et al.. (2015). Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Blood. 126(23). 587–587. 12 indexed citations
10.
Fong, Abraham, Zizhen Yao, Jun Zhong, et al.. (2015). Conversion of MyoD to a Neurogenic Factor: Binding Site Specificity Determines Lineage. Cell Reports. 10(12). 1937–1946. 46 indexed citations
11.
MacQuarrie, Kyle L., Zizhen Yao, Abraham Fong, & Stephen J. Tapscott. (2013). Genome-wide binding of the basic helix-loop-helix myogenic inhibitor musculin has substantial overlap with MyoD: implications for buffering activity. Skeletal Muscle. 3(1). 26–26. 13 indexed citations
12.
Yao, Zizhen, Abraham Fong, Yi Cao, et al.. (2013). Comparison of endogenous and overexpressed MyoD shows enhanced binding of physiologically bound sites. Skeletal Muscle. 3(1). 8–8. 20 indexed citations
13.
Yao, Zizhen, Kyle L. MacQuarrie, Abraham Fong, et al.. (2013). Discriminative motif analysis of high-throughput dataset. Bioinformatics. 30(6). 775–783. 31 indexed citations
14.
Fong, Abraham & Stephen J. Tapscott. (2013). Skeletal muscle programming and re-programming. Current Opinion in Genetics & Development. 23(5). 568–573. 69 indexed citations
15.
Fong, Abraham, Zizhen Yao, Jun Zhong, et al.. (2012). Genetic and Epigenetic Determinants of Neurogenesis and Myogenesis. Developmental Cell. 22(4). 721–735. 87 indexed citations
16.
MacQuarrie, Kyle L., Zizhen Yao, Abraham Fong, et al.. (2012). Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors. Molecular and Cellular Biology. 33(4). 773–784. 54 indexed citations
17.
Geng, Linda N., Zizhen Yao, Lauren Snider, et al.. (2011). DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy. Developmental Cell. 22(1). 38–51. 339 indexed citations
18.
MacQuarrie, Kyle L., Abraham Fong, Randall H. Morse, & Stephen J. Tapscott. (2011). Genome-wide transcription factor binding: beyond direct target regulation. Trends in Genetics. 27(4). 141–148. 175 indexed citations
19.
Fong, Abraham & Julie R. Park. (2009). HIGH-RISK NEUROBLASTOMA: A Therapy in Evolution. Pediatric Hematology and Oncology. 26(8). 539–548. 12 indexed citations
20.
Dvorak, Christopher C., et al.. (2008). Maternal T-cell Engraftment Associated With Severe Hemophagocytosis of the Bone Marrow in Untreated X-linked Severe Combined Immunodeficiency. Journal of Pediatric Hematology/Oncology. 30(5). 396–400. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaret E. Macy Breakdown of academic impact, for papers by Najim Ameziane Breakdown of academic impact, for papers by Roberta Sestini Breakdown of academic impact, for papers by Adam D. Durbin Breakdown of academic impact, for papers by MA Shipp Breakdown of academic impact, for papers by Inga Nagel Breakdown of academic impact, for papers by Suvi Savola Breakdown of academic impact, for papers by Alison Z. Young Breakdown of academic impact, for papers by Carrie Fitzpatrick Breakdown of academic impact, for papers by Shalini C. Reshmi
Rankless by CCL
2026